Fri, 26 Apr 2019 07:36:05 GMT
Roche's Spark deal delayed amid FTC review
On Friday, Roche announced it would again extend its $4.3B proposal for Spark Therapeutics, the gene therapy specialist, until June 3 due to the Federal Trade Commission's review of the potential deal.